Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.

West Nile Virus Spreads Transsynaptically within the Pathways of Motor Control: Anatomical and Ultrastructural Mapping of Neuronal Virus Infection in the Primate Central Nervous System. PLoS Negl Trop Dis (2016) 0.76

A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis (2016) 0.75

Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (1999) 18.55

Isolation from human sera in Egypt of a virus apparently identical to West Nile virus. Proc Soc Exp Biol Med (1951) 3.10

A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67

Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill Summ (2010) 2.47

Study on West Nile virus persistence in monkeys. Arch Virol (1983) 2.43

West Nile virus neuroinvasive disease. Ann Neurol (2006) 2.42

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis (2011) 2.25

Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect (2012) 1.78

A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A (2006) 1.72

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A (2002) 1.65

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol (2004) 1.50

A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis (2011) 1.42

West Nile Virus: biology, transmission, and human infection. Clin Microbiol Rev (2012) 1.38

Macaque models of human infectious disease. ILAR J (2008) 1.38

Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine (2006) 1.36

Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Hum Pathol (2004) 1.26

Nonhuman primate models of human immunology. Antioxid Redox Signal (2010) 1.26

Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis (2004) 1.25

West Nile virus meningoencephalitis. Nat Clin Pract Neurol (2006) 1.22

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology (2003) 1.19

Flavivirus encephalitis: pathological aspects of mouse and other animal models. Vet Pathol (2010) 1.15

Resurgence of West Nile neurologic disease in the United States in 2012: what happened? What needs to be done? Antiviral Res (2013) 1.13

West nile virus disease and other arboviral diseases - United States, 2011. MMWR Morb Mortal Wkly Rep (2012) 1.09

Recent progress in West Nile virus diagnosis and vaccination. Vet Res (2012) 1.09

Neuropathology of experimental West Nile virus infection in monkeys. J Neuropathol Exp Neurol (1956) 1.05

Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors. Vector Borne Zoonotic Dis (2005) 1.04

Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy (2011) 1.04

Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis (2006) 1.04

Unpredictable and difficult to control--the adolescence of West Nile virus. N Engl J Med (2012) 1.02

Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates. J Virol (2008) 1.01

West Nile virus infections. J Neuropathol Exp Neurol (2009) 1.01

Baboon model for West Nile virus infection and vaccine evaluation. Virology (2006) 0.99

West Nile virus infection in nonhuman primate breeding colony, concurrent with human epidemic, southern Louisiana. Emerg Infect Dis (2003) 0.99

Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol (2009) 0.97

Histological studies of the monkey neurovirulence of group B arboviruses. 3. Relative virulence of selected viruses. Am J Epidemiol (1967) 0.92

West nile virus neuroinvasive disease. Curr Infect Dis Rep (2011) 0.91

Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. Vaccine (2012) 0.90

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine (2013) 0.89

Immune response to the West Nile virus in aged non-human primates. PLoS One (2010) 0.86

Cellular inflammatory response to flaviviruses in the central nervous system of a primate host. J Histochem Cytochem (2009) 0.82

Public health. Outbreak pattern stymies vaccine work. Science (2012) 0.81

West Nile Virus: is a vaccine needed? Curr Opin Investig Drugs (2010) 0.78

Silencing of neurotropic flavivirus replication in the central nervous system by combining multiple microRNA target insertions in two distinct viral genome regions. Virology (2014) 0.82